An evaluation of the patient population for aesthetic treatments targeting abdominal subcutaneous adipose tissue

Authors

  • Daniel P Friedmann MD, FAAD,

    Corresponding author
    1. Westlake Dermatology Clinical Research Center, Westlake Dermatology & Cosmetic Surgery, Austin, TX, USA
    • Correspondence: Daniel P Friedmann, MD, Goldman, Butterwick, Fitzpatrick, Groff & Fabi: Cosmetic Laser Dermatology, 9339 Genesee Ave, Ste 300, San Diego, CA 92121, USA. E-mail: danf2300@gmail.com

    Search for more papers by this author
  • Mathew M Avram MD, JD, FAAD,

    1. Dermatology Laser and Cosmetic Center and Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Search for more papers by this author
  • Steven R Cohen MD, FACS,

    1. Division of Plastic Surgery, University of California at San Diego, San Diego, CA, USA
    2. FACES+ Plastic Surgery, Skin and Laser Center, San Diego, CA, USA
    Search for more papers by this author
  • Diane I Duncan MD, FACS,

    1. Plastic Surgical Associates of Fort Collins, P.C., Fort Collins, CO, USA
    Search for more papers by this author
  • Mitchel P Goldman MD, FAAD, FACPh, FAACS,

    1. Department of Dermatology, University of California at San Diego, San Diego, CA, USA
    2. Goldman, Butterwick, Fitzpatrick, Groff & Fabi: Cosmetic Laser Dermatology, San Diego, CA, USA
    Search for more papers by this author
  • Elliot T Weiss MD, FAAD,

    1. Department of Dermatology, Weil-Cornell Medical College, New York, NY, USA
    2. Laser and Skin Surgery Center of New York, New York, NY, USA
    Search for more papers by this author
  • V Leroy Young MD, FACS

    1. Body Aesthetic Plastic Surgery and Skincare Center, St. Louis, MO, USA
    Search for more papers by this author

Summary

A large and growing population of patients currently seeks minimally invasive therapeutic options for the aesthetic treatment of localized, central abdominal subcutaneous adipose tissue (SAT). We sought to evaluate the ideal population for aesthetic treatment of central abdominal SAT, highlight the existing disparities between SAT in obese (body mass index [BMI] ≥ 30; BMI) and nonobese (BMI < 30) patients, and review the available FDA-cleared, minimally invasive treatment options for central abdominal adiposity. The cosmetic issue of localized, central (periumbilical) abdominal adiposity in nonobese individuals is quite distinct from abdominal bulging secondary to obesity. Given the recognized clinical and physiologic differences between obese and nonobese counterparts, the exclusion of obese patients from clinical study by currently available FDA-cleared devices targeting abdominal fat, and the status of obesity as a chronic, systemic disease requiring medical, surgical, and/or lifestyle-altering therapies, minimally invasive therapeutic options for aesthetic reductions in central abdominal SAT must be limited to the nonobese population.

Ancillary